NDI-034858 (TAK-279) is a tyrosine kinase 2 (TYK2) inhibitor (Kd<200 pM) that targets the JH2 structural domain of Tyk2 for the treatment of autoimmune diseases caused by aberrant expression of IL12 and IL23.

Tyrosinase-IN-2 (compound 67) is a potent inhibitor of tyrosinase, a copper-containing metalloenzyme crucial for the rate-limiting step in melanin biosynthesis and enzymatic browning processes.

Tafetinib (SIM-010603) is a novel potent and orally available tyrosine kinase inhibitor with anti-angiogenic and anti-tumour activity.